<DOC>
	<DOCNO>NCT01718366</DOCNO>
	<brief_summary>Determinate safety response rate association Deferasirox -Vitamine D - Azacitidine treatment high risk MDS Deferasirox Exjade : The dose Deferasirox assign accord ferritin level . Dose escalation schedule phase I , 5 additional patient per group . The maximal tolerate dose Deferasirox require phase II study . The first dose assign accord ferritin level patient time inclusion : 5 mg/kg/d ferritin &gt; 300ng/ml &lt; 1000ng/ml Group 1 10 mg/kg/d ferritin ≥1000ng/ml ) Group 2 Group 1 : Ferritin 300 1000ng /ml : - cohort 1 : 5 mg/kg/d - cohort 2 : 10mg/kg/d - cohort 3 : 15 mg/kg/d Group 2 : Ferritin &gt; 1000ng /ml : - cohort 1 : 10 mg/kg/d - cohort 2 : 15mg/kg/d - cohort 3 : 20 mg/kg/d 5 patient treated cohort . In absence toxicity ( extra-hematological toxicity grade 3 4 hematological grade 4 ) , 5 additional patient include next cohort . Deferasirox administrate daily study period . Uvedose administrate weekly study period ( 100.000 UI P.O ) . Azacitidine administrate sc 75 mg/m²/d , 7 day , J1 J7 cycle ( One cycle 28 day ) During phase I II , Deferasirox always associate Vitamin D Azacitidine Patients receive 6 cycle treatment ( except progression , unacceptable toxicity withdrawn patient occur ) After 3 6 cycle , evaluation do evaluate efficacy treatment . No dose modification deferasirox do 3 cycle treatment except case progression ) . After 6 cycle , patient CR , PR , marrow CR HI treat dose Deferasirox progression .</brief_summary>
	<brief_title>A Study Combined Deferasirox , Vitamin D Azacytidine High Risk MDS</brief_title>
	<detailed_description>Deferasirox administrate daily morning empty stomach , 30 minute meal . Deferasirox stop ferritin level 100 ng/ml , could restart ferritin level increase 200 ng/ml Uvedose dose could adjust accord phosphocalcic metabolism parameter plasma Vitamin D3 level .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>High risk MDS , accord OMS classification High risk CMML ( WBC &lt; 13 G/L ) AREBT FAB classification le 30 % blastes IPSS &gt; =1.5 ( int2 high risk ) Age &gt; =18y Performance status &lt; =2 ( ECOG ) Bilirubin transaminase &lt; 1.5 x ULN Normal renal function Patient eligible Allogeneic stem cell transplant Male female patient must use effective contraceptive method study minimum 3 month study treatment . Agree need use condom engage sexual activity pregnant woman woman childbearing potential . entire period treatment , even disruption treatment 3 month end treatment Male patient : Agree conceive treatment study drug therapy ( include dos interruption ) 3 month end study drug therapy Agree donate semen study drug therapy one week end study drug therapy . Agree learn procedure preservation sperm , start treatment Patient able adhere study visit schedule protocol requirement Active infection uncontrolled disease Use cytotoxic chemotherapeutic agent experimental agent ( agent commercially available ) treatment MDS within 28 day . In case use cytotoxic chemotherapeutic agent hypomethylating agent wash 3 mont require . Active Cancer Cancer within one year inclusion Previous calcic urinary lithiasis Previous hyperparathyroid primitive disease uncontrolled Hypercalcemia , hyperphosphoremia , hypervitaminosis D Patient already include another experimental study Active infection HIV , hepatite B C Pregnant lactate female Patient able ( medical/psychiatric ) understand sign write consent Patients ferritin level le 300ng/ml Patient eligible Allogeneic stem cell transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>